Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Everything but the Kitchen Sink: IoM Drug Safety Report Gives FDA Options

This article was originally published in RPM Report

Executive Summary

The Institute of Medicine's drug safety committee came down hard on FDA's efforts to make sure drugs they approve are safe and effective. But FDA dodged a bullet based on what isn't in the report.

You may also be interested in...



The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability

Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.

The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability

Janet Woodcock is returning as director of CDER at a time when the user fee program is in flux and FDA is struggling to implement new drug safety initiatives. For 2008, timeliness of reviews will slip, but with any luck, the transparency and predictability of PDUFA will continue.

Avandia's Black Box: FDA's Office of New Drugs Wins

The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel